Kliniska studier vid Tema Cancer

Predicting fatigue after allo HSCT. Predicting chronic fatigue and cognitive dysfunction after allogeneic hematopoietic stem cell transplant.

Katarina Le Blanc

LTFU - CAR T-Cell. Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CAR T-Cell Therapy)

Stephan Mielke

Alexion 1210 TMA-313. A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT

Ksenia Boriskina

PerCent-aCent. Personcentrerad vård inom allo-HSCT

Jeanette Winterling

NMDSG14-B-2. A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syndrome - MDS

Andreas Björklund

Claudin-6 BNT211-01. Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors

Stephan Mielke

Fatigue PET studie. Fatigue och kognitiv dysfunktion till följd av synaptopati eller Graft versus host (GVH) sjukdom i hjärnan

Katarina Le Blanc

ROCKnrol-1. A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)[Protocol number: EFC17757]

Johan Törlén

CA0881007-Myelom. A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5Ddirected CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomiderefractory Multiple Myeloma

Johan Törlén